{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:14:04Z","timestamp":1771877644865,"version":"3.50.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","award":["BD-9365"],"award-info":[{"award-number":["BD-9365"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003968","name":"Iran National Science Foundation","doi-asserted-by":"publisher","award":["96011491"],"award-info":[{"award-number":["96011491"]}],"id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-76851-7","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T14:04:04Z","timestamp":1729692244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti-IL-1RAP scFv-mSA-S19-TAT fusion carrier as a multifunctional platform for versatile delivery of biotinylated payloads to myeloid leukemia cells"],"prefix":"10.1038","volume":"14","author":[{"given":"Aref","family":"Farokhi-Fard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saman","family":"Rahmati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Negin Sadat","family":"Hashemi Aval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzaneh","family":"Barkhordari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Bayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Komijani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hooman","family":"Aghamirza Moghim Aliabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Davami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"76851_CR1","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/cncr.22233","volume":"107","author":"B 1 Deschler","year":"2006","unstructured":"1 Deschler, B. & L\u00fcbbert, M. Acute myeloid leukemia: epidemiology and etiology. Cancer Interdiscip. Int. J. Am. Cancer Soc. 107, 2099\u20132107. https:\/\/doi.org\/10.1002\/cncr.22233 (2006).","journal-title":"Cancer Interdiscip. Int. J. Am. Cancer Soc."},{"key":"76851_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/medicina54010005","volume":"54","author":"N Maksimovic","year":"2018","unstructured":"Maksimovic, N. et al. Incidence and mortality patterns of Acute myeloid leukemia in Belgrade, Serbia (1999\u20132013). Med. 54, 5. https:\/\/doi.org\/10.3390\/medicina54010005 (2018).","journal-title":"Med"},{"key":"76851_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis, R. M., Wang, R., Davidoff, A., Ma, X. & Zeidan, A. M. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 36, 70\u201387. https:\/\/doi.org\/10.1016\/j.blre.2019.04.005 (2019).","journal-title":"Blood Rev."},{"key":"76851_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/1097-0142(195101)4","volume":"4","author":"CM Southam","year":"1951","unstructured":"Southam, C. M., Craver, L. F., Dargeon, H. W. & Burchenal, J. H. A study of the natural history of acute leukemia with special reference to the duration of the disease and the occurrence of remissions. Cancer. 4, 39\u201359. https:\/\/doi.org\/10.1002\/1097-0142(195101)4 (1951). :1%3C39::AID-CNCR2820040105%3E3.0.CO;2-G.","journal-title":"Cancer"},{"key":"76851_CR5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1200\/JCO.2014.60.0890","volume":"98","author":"E Cheung","year":"2019","unstructured":"Cheung, E. et al. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. Ann. Hematol. 98, 541\u2013559. https:\/\/doi.org\/10.1200\/JCO.2014.60.0890 (2019).","journal-title":"Ann. Hematol."},{"key":"76851_CR6","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1182\/blood-2006-04-015560","volume":"108","author":"S Knapper","year":"2006","unstructured":"Knapper, S. et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 108, 3262\u20133270. https:\/\/doi.org\/10.1182\/blood-2006-04-015560 (2006).","journal-title":"Blood"},{"key":"76851_CR7","doi-asserted-by":"publisher","first-page":"931050","DOI":"10.3389\/fonc.2022.931050","volume":"12","author":"IV Barreto","year":"2022","unstructured":"Barreto, I. V. et al. Leukemic stem cell: a mini-review on clinical perspectives. Front. Oncol. 12, 931050. https:\/\/doi.org\/10.3389\/fonc.2022.931050 (2022).","journal-title":"Front. Oncol."},{"key":"76851_CR8","unstructured":"Afessa, B. & Peters, S. G. in Semin. Respir. Crit. Care Med.. 297\u2013309 (Thieme Medical Publishers, Inc)."},{"key":"76851_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","volume":"36","author":"S Tettamanti","year":"2022","unstructured":"Tettamanti, S., Pievani, A., Biondi, A., Dotti, G. & Serafini, M. Catch me if you can: how AML and its niche escape immunotherapy. Leuk. 36, 13\u201322. https:\/\/doi.org\/10.1038\/s41375-021-01350-x (2022).","journal-title":"Leuk"},{"key":"76851_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2217\/imt.13.152","volume":"6","author":"M Arpinati","year":"2014","unstructured":"Arpinati, M. & Curti, A. Immunotherapy in acute myeloid leukemia. Immunother. 6, 95\u2013106. https:\/\/doi.org\/10.2217\/imt.13.152 (2014).","journal-title":"Immunother"},{"key":"76851_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/MPH.0b013e318266c0c8","volume":"35","author":"A Reilly","year":"2013","unstructured":"Reilly, A. et al. Immunologic consequences of chemotherapy for acute myeloid leukemia. J. Pediatr. Hematol. Oncol. 35, 46. https:\/\/doi.org\/10.1097\/MPH.0b013e318266c0c8 (2013).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"76851_CR12","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1038\/bcj.2015.110","volume":"6","author":"K Bochennek","year":"2016","unstructured":"Bochennek, K. et al. Infectious complications in children with acute myeloid leukemia: decreased mortality in multicenter trial AML-BFM 2004. Blood Cancer J. 6, e382\u2013e382. https:\/\/doi.org\/10.1038\/bcj.2015.110 (2016).","journal-title":"Blood Cancer J."},{"key":"76851_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.20.00475","volume":"39","author":"S Khaldoyanidi","year":"2021","unstructured":"Khaldoyanidi, S., Nagorsen, D., Stein, A., Ossenkoppele, G. & Subklewe, M. Immune biology of acute myeloid leukemia: implications for immunotherapy. J. Clin. Oncol. 39, 419. https:\/\/doi.org\/10.1200%2FJCO.20.00475 (2021).","journal-title":"J. Clin. Oncol."},{"key":"76851_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.12691\/jcrt-5-2-4","volume":"5","author":"A Kabel","year":"2017","unstructured":"Kabel, A., Zamzami, F., Al-Talhi, M., Al-Dwila, K. & Hamza, R. Acute myeloid leukemia: a focus on risk factors, clinical presentation, diagnosis and possible lines of management. Cancer Res. Treat. 5, 62\u201367. https:\/\/doi.org\/10.12691\/jcrt-5-2-4 (2017).","journal-title":"Cancer Res. Treat."},{"key":"76851_CR15","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","volume":"114","author":"R Le Dieu","year":"2009","unstructured":"Le Dieu, R. et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood. 114, 3909\u20133916. https:\/\/doi.org\/10.1182\/blood-2009-02-206946 (2009).","journal-title":"Blood"},{"key":"76851_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1834-7819.2009.01129.x","volume":"54","author":"F Santos","year":"2009","unstructured":"Santos, F. et al. Severe necrotizing stomatitis and osteomyelitis after chemotherapy for acute leukaemia. Aust Dent. J. 54, 262\u2013265. https:\/\/doi.org\/10.1111\/j.1834-7819.2009.01129.x (2009).","journal-title":"Aust Dent. J."},{"key":"76851_CR17","doi-asserted-by":"publisher","first-page":"764698","DOI":"10.3389\/fcell.2021.764698","volume":"9","author":"DB Pimenta","year":"2021","unstructured":"Pimenta, D. B. et al. The bone marrow microenvironment mechanisms in acute myeloid leukemia. Front. Cell. Dev. Biol. 9, 764698. https:\/\/doi.org\/10.3389\/fcell.2021.764698 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"76851_CR18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1586\/17474086.2014.958464","volume":"7","author":"A Isidori","year":"2014","unstructured":"Isidori, A. et al. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. Expert Rev. Hematol. 7, 807\u2013818. https:\/\/doi.org\/10.1586\/17474086.2014.958464 (2014).","journal-title":"Expert Rev. Hematol."},{"key":"76851_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.blre.2018.12.001","volume":"34","author":"Y Liu","year":"2019","unstructured":"Liu, Y., Bewersdorf, J. P., Stahl, M. & Zeidan, A. M. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: the dawn of a new era? Blood Rev. 34, 67\u201383 (2019).","journal-title":"Blood Rev."},{"key":"76851_CR20","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","volume":"123","author":"S Gill","year":"2014","unstructured":"Gill, S. et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor\u2013modified T cells. Blood J. Am. Soc. Hematol. 123, 2343\u20132354. https:\/\/doi.org\/10.1182\/blood-2013-09-529537 (2014).","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"76851_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40164-024-00490-x","volume":"13","author":"Z Liu","year":"2024","unstructured":"Liu, Z., Lei, W., Wang, H., Liu, X. & Fu, R. Challenges and strategies associated with CAR-T cell therapy in blood malignancies. Exp. Hematol. Oncol. 13, 22. https:\/\/doi.org\/10.1186\/s40164-024-00490-x (2024).","journal-title":"Exp. Hematol. Oncol."},{"key":"76851_CR22","doi-asserted-by":"publisher","first-page":"14918","DOI":"10.3390\/ijms232314918","volume":"23","author":"J Frenay","year":"2022","unstructured":"Frenay, J. et al. IL-1RAP, a key therapeutic target in cancer. Int. J. Mol. Sci. 23, 14918 (2022). https:\/\/www.mdpi.com\/1422-0067\/23\/23\/14918#","journal-title":"Int. J. Mol. Sci."},{"key":"76851_CR23","doi-asserted-by":"publisher","first-page":"16280","DOI":"10.1073\/pnas.1004408107","volume":"107","author":"M J\u00e4r\u00e5s","year":"2010","unstructured":"J\u00e4r\u00e5s, M. et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc. Natl. Acad. Sci. 107, 16280\u201316285. https:\/\/doi.org\/10.1073\/pnas.1004408107 (2010).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"76851_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1158\/0008-5472.CAN-18-1078","volume":"79","author":"W Warda","year":"2019","unstructured":"Warda, W. et al. CML hematopoietic stem cells expressing IL1RAP can be targeted by chimeric antigen receptor\u2013engineered T cells. Cancer Res. 79, 663\u2013675. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1078 (2019).","journal-title":"Cancer Res."},{"key":"76851_CR25","doi-asserted-by":"publisher","first-page":"10786","DOI":"10.1073\/pnas.1422749112","volume":"112","author":"H \u00c5gerstam","year":"2015","unstructured":"\u00c5gerstam, H. et al. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proc. Natl. Acad. Sci. 112, 10786\u201310791. https:\/\/doi.org\/10.1073\/pnas.1422749112 (2015).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"76851_CR26","first-page":"4787","volume":"7","author":"K Zhao","year":"2014","unstructured":"Zhao, K. et al. IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients. Int. J. Clin. Exp. Med. 7, 4787 (2014).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"76851_CR27","doi-asserted-by":"crossref","unstructured":"Trad, R. et al. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. J. Immunother. Cancer 10 (2022).","DOI":"10.1136\/jitc-2021-004222"},{"key":"76851_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-024-01586-x","volume":"17","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells. J. Hematol. Oncol. 17, 67. https:\/\/doi.org\/10.1186\/s13045-024-01586-x (2024).","journal-title":"J. Hematol. Oncol."},{"key":"76851_CR29","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1158\/1538-7445.AM2024-2360","volume":"84","author":"RC Sainson","year":"2024","unstructured":"Sainson, R. C. et al. ADV101, a first-in-class IL-1RAP ADC demonstrates significant anti-tumor activity in solid tumor models. Cancer Res. 84, 2360\u20132360. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-2360 (2024).","journal-title":"Cancer Res."},{"key":"76851_CR30","doi-asserted-by":"publisher","unstructured":"Wu, X. et al. Advances in drug delivery systems for the treatment of acute myeloid leukemia. Small. 2403409 https:\/\/doi.org\/10.1002\/smll.202403409 (2024).","DOI":"10.1002\/smll.202403409"},{"key":"76851_CR31","doi-asserted-by":"crossref","unstructured":"Li, F. et al. Recent advances in material technology for leukemia treatments. Adv. Mater., 2313955 (2024).","DOI":"10.1002\/adma.202313955"},{"key":"76851_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2017.03.398","volume":"255","author":"K Sudo","year":"2017","unstructured":"Sudo, K. et al. Human-derived fusogenic peptides for the intracellular delivery of proteins. J. Control Release. 255, 1\u201311. https:\/\/doi.org\/10.1016\/j.jconrel.2017.03.398 (2017).","journal-title":"J. Control Release"},{"key":"76851_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nm996","volume":"10","author":"JS Wadia","year":"2004","unstructured":"Wadia, J. S., Stan, R. V. & Dowdy, S. F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10, 310\u2013315. https:\/\/doi.org\/10.1038\/nm996 (2004).","journal-title":"Nat. Med."},{"key":"76851_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jconrel.2004.10.018","volume":"102","author":"IM Kaplan","year":"2005","unstructured":"Kaplan, I. M., Wadia, J. S. & Dowdy, S. F. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J. Control Release. 102, 247\u2013253. https:\/\/doi.org\/10.1016\/j.jconrel.2004.10.018 (2005).","journal-title":"J. Control Release"},{"key":"76851_CR35","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ymthe.2004.08.010","volume":"10","author":"I Nakase","year":"2004","unstructured":"Nakase, I. et al. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol. Ther. 10, 1011\u20131022. https:\/\/doi.org\/10.1016\/j.ymthe.2004.08.010 (2004).","journal-title":"Mol. Ther."},{"key":"76851_CR36","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/icb.2011.20","volume":"89","author":"JP Lim","year":"2011","unstructured":"Lim, J. P. & Gleeson, P. A. Macropinocytosis: an endocytic pathway for internalising large gulps. Immunol. Cell. Biol. 89, 836\u2013843. https:\/\/doi.org\/10.1038\/icb.2011.20 (2011).","journal-title":"Immunol. Cell. Biol."},{"key":"76851_CR37","doi-asserted-by":"publisher","unstructured":"Maxfield, F. R. & Yamashiro, D. J. Endosome acidification and the pathways of receptor-mediated endocytosis. Immunobiol. Proteins pept. IV. 189\u2013198. https:\/\/doi.org\/10.1007\/978-1-4684-5442-0_16 (1987).","DOI":"10.1007\/978-1-4684-5442-0_16"},{"key":"76851_CR38","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1038\/emboj.2011.286","volume":"30","author":"J Huotari","year":"2011","unstructured":"Huotari, J. & Helenius, A. Endosome maturation. EMBO j. 30, 3481\u20133500. https:\/\/doi.org\/10.1038\/emboj.2011.286 (2011).","journal-title":"EMBO J."},{"key":"76851_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.biochi.2019.02.012","volume":"160","author":"A Ahmad","year":"2019","unstructured":"Ahmad, A., Khan, J. M. & Haque, S. Strategies in the design of endosomolytic agents for facilitating endosomal escape in nanoparticles. Biochim. 160, 61\u201375. https:\/\/doi.org\/10.1016\/j.biochi.2019.02.012 (2019).","journal-title":"Biochim"},{"key":"76851_CR40","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.004","volume":"151","author":"AK Varkouhi","year":"2011","unstructured":"Varkouhi, A. K., Scholte, M., Storm, G. & Haisma, H. J. Endosomal escape pathways for delivery of biologicals. J. Control Release. 151, 220\u2013228. https:\/\/doi.org\/10.1016\/j.jconrel.2010.11.004 (2011).","journal-title":"J. Control Release"},{"key":"76851_CR41","doi-asserted-by":"publisher","unstructured":"L\u00f6nn, P. et al. Enhancing endosomal escape for intracellular delivery of macromolecular biologic therapeutics. Sci. Rep. 6, 32301. https:\/\/doi.org\/10.1038\/srep32301 (2016).","DOI":"10.1038\/srep32301"},{"key":"76851_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bbrc.2021.11.065","volume":"586","author":"M Suzuki","year":"2022","unstructured":"Suzuki, M., Iwaki, K., Kikuchi, M., Fujiwara, K. & Doi, N. Characterization of the membrane penetration-enhancing peptide S19 derived from human syncytin-1 for the intracellular delivery of TAT-fused proteins. Biochem. Biophys. Res. Commun. 586, 63\u201367. https:\/\/doi.org\/10.1016\/j.bbrc.2021.11.065 (2022).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"76851_CR43","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s12951-022-01667-4","volume":"20","author":"M Nakamura","year":"2022","unstructured":"Nakamura, M., Fujiwara, K. & Doi, N. Cytoplasmic delivery of siRNA using human-derived membrane penetration-enhancing peptide. J. Nanobiotechnol. 20, 458. https:\/\/doi.org\/10.1186\/s12951-022-01667-4 (2022).","journal-title":"J. Nanobiotechnol."},{"key":"76851_CR44","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.pep.2003.07.001","volume":"32","author":"HP S\u00f8rensen","year":"2003","unstructured":"S\u00f8rensen, H. P., Sperling-Petersen, H. U. & Mortensen, K. K. A favorable solubility partner for the recombinant expression of streptavidin. Protein Expr. Purif. 32, 252\u2013259. https:\/\/doi.org\/10.1016\/j.pep.2003.07.001 (2003).","journal-title":"Protein Expr. Purif."},{"key":"76851_CR45","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s11033-022-07972-3","volume":"50","author":"A Farokhi-Fard","year":"2023","unstructured":"Farokhi-Fard, A. et al. Bacterial production and biophysical characterization of a hard-to-fold scFv against myeloid leukemia cell surface marker, IL-1RAP. Mol. Biol. Rep. 50, 1191\u20131202. https:\/\/doi.org\/10.1007\/s11033-022-07972-3 (2023).","journal-title":"Mol. Biol. Rep."},{"key":"76851_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jconrel.2016.11.016","volume":"245","author":"A Jain","year":"2017","unstructured":"Jain, A. & Cheng, K. The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis. J. Controlled Release. 245, 27\u201340 (2017).","journal-title":"J. Controlled Release"},{"key":"76851_CR47","doi-asserted-by":"publisher","unstructured":"Rinne, J. et al. 188. Internalization of novel delivery vector TAT-streptavidin into human cells. Mol. Ther. 13, S73, (2006). https:\/\/doi.org\/10.1016\/j.ymthe.2006.08.212","DOI":"10.1016\/j.ymthe.2006.08.212"},{"key":"76851_CR48","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/protein\/9.2.203","volume":"9","author":"SM Kipriyanov","year":"1996","unstructured":"Kipriyanov, S. M. et al. Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain fv fragment\u2013core streptavidin fusion. Protein Eng. Des. Sel. 9, 203\u2013211. https:\/\/doi.org\/10.1093\/protein\/9.2.203 (1996).","journal-title":"Protein Eng. Des. Sel."},{"key":"76851_CR49","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1021\/jacs.9b13621","volume":"142","author":"J L\u00f3pez-Andarias","year":"2020","unstructured":"L\u00f3pez-Andarias, J. et al. Cell-penetrating streptavidin: a general tool for bifunctional delivery with spatiotemporal control, mediated by transport systems such as adaptive benzopolysulfane networks. J. Am. Chem. Soc. 142, 4784\u20134792. https:\/\/doi.org\/10.1021\/jacs.9b13621 (2020).","journal-title":"J. Am. Chem. Soc."},{"key":"76851_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jconrel.2016.11.016","volume":"245","author":"A Jain","year":"2017","unstructured":"Jain, A. & Cheng, K. The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis. J. Control Release. 245, 27\u201340. https:\/\/doi.org\/10.1016\/j.jconrel.2016.11.016 (2017).","journal-title":"J. Control Release"},{"key":"76851_CR51","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.2967\/jnumed.121.262186","volume":"63","author":"SM Cheal","year":"2022","unstructured":"Cheal, S. M., Chung, S. K., Vaughn, B. A., Cheung, N. K. V. & Larson, S. M. Pretargeting: a path forward for radioimmunotherapy. J. Nucl. Med. 63, 1302\u20131315. https:\/\/doi.org\/10.2967\/jnumed.121.262186 (2022).","journal-title":"J. Nucl. Med."},{"key":"76851_CR52","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3109\/1061186X.2012.712128","volume":"20","author":"W Sun","year":"2012","unstructured":"Sun, W., Fletcher, D., van Heeckeren, R. C. & Davis, P. B. Non-covalent ligand conjugation to biotinylated DNA nanoparticles using TAT peptide genetically fused to monovalent streptavidin. J. Drug Target. 20, 678\u2013690. https:\/\/doi.org\/10.3109\/1061186X.2012.712128 (2012).","journal-title":"J. Drug Target."},{"key":"76851_CR53","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3390\/ph5111177","volume":"5","author":"A Erazo-Oliveras","year":"2012","unstructured":"Erazo-Oliveras, A., Muthukrishnan, N., Baker, R., Wang, T. Y. & Pellois, J. P. Improving the endosomal escape of cell-penetrating peptides and their cargos: strategies and challenges. Pharm. 5, 1177\u20131209. https:\/\/doi.org\/10.3390\/ph5111177 (2012).","journal-title":"Pharm"},{"key":"76851_CR54","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1021\/bc7004076","volume":"19","author":"RJ Boado","year":"2008","unstructured":"Boado, R. J. et al. Genetic engineering, expression, and activity of a chimeric monoclonal antibody\u2009\u2013\u2009avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. Bioconjug. Chem. 19, 731\u2013739. https:\/\/doi.org\/10.1021\/bc7004076 (2008).","journal-title":"Bioconjug. Chem."},{"key":"76851_CR55","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1021\/bc200174x","volume":"22","author":"QH Zhou","year":"2011","unstructured":"Zhou, Q. H., Lu, J. Z., Hui, E. K. W., Boado, R. J. & Pardridge, W. M. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein. Bioconjug. Chem. 22, 1611\u20131618. https:\/\/doi.org\/10.1021\/bc200174x (2011).","journal-title":"Bioconjug. Chem."},{"key":"76851_CR56","doi-asserted-by":"publisher","first-page":"6285","DOI":"10.1007\/s00253-014-5682-y","volume":"98","author":"D Demonte","year":"2014","unstructured":"Demonte, D., Dundas, C. M. & Park, S. Expression and purification of soluble monomeric streptavidin in Escherichia coli. Appl. Microbiol. Biotechnol. 98, 6285\u20136295. https:\/\/doi.org\/10.1007\/s00253-014-5682-y (2014).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"76851_CR57","doi-asserted-by":"crossref","unstructured":"Trad, R. et al. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. J. Immunother Cancer. 10 https:\/\/doi.org\/10.1136%2Fjitc-2021-004222 (2022).","DOI":"10.1136\/jitc-2021-004222"},{"key":"76851_CR58","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1182\/bloodadvances.2021005018","volume":"6","author":"R Houtsma","year":"2022","unstructured":"Houtsma, R. et al. CombiFlow: combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones. Blood Adv. 6, 2129\u20132143. https:\/\/doi.org\/10.1182\/bloodadvances.2021005018 (2022).","journal-title":"Blood Adv."},{"key":"76851_CR59","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2012-01-404699","volume":"120","author":"L Barreyro","year":"2012","unstructured":"Barreyro, L. et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood J. Am. Soc. Hematol. 120, 1290\u20131298. https:\/\/doi.org\/10.1182\/blood-2012-01-404699 (2012).","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"76851_CR60","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/hep.20053","volume":"39","author":"JW Kim","year":"2004","unstructured":"Kim, J. W. et al. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatol. 39, 518\u2013527. https:\/\/doi.org\/10.1002\/hep.20053 (2004).","journal-title":"Hepatol"},{"key":"76851_CR61","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1158\/2159-8290.CD-20-1690","volume":"11","author":"HF Zhang","year":"2021","unstructured":"Zhang, H. F. et al. Proteomic screens for suppressors of anoikis identify IL1RAP as a promising surface target in ewing sarcoma. Cancer Discov. 11, 2884\u20132903. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1690 (2021).","journal-title":"Cancer Discov"},{"key":"76851_CR62","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-022-01286-4","volume":"15","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer. J. Hematol. Oncol. 15, 70. https:\/\/doi.org\/10.1186\/s13045-022-01286-4 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"76851_CR63","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"S Jones","year":"2008","unstructured":"Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Sci. 321, 1801\u20131806. https:\/\/doi.org\/10.1126\/science.1164368 (2008).","journal-title":"Sci"},{"key":"76851_CR64","doi-asserted-by":"publisher","first-page":"153141","DOI":"10.1016\/j.prp.2020.153141","volume":"216","author":"F Li","year":"2020","unstructured":"Li, F., Zhang, W., Wang, M. & Jia, P. IL1RAP regulated by PRPRD promotes gliomas progression via inducing neuronal synapse development and neuron differentiation in vitro. Pathol. Res. Pract. 216, 153141. https:\/\/doi.org\/10.1016\/j.prp.2020.153141 (2020).","journal-title":"Pathol. Res. Pract."},{"key":"76851_CR65","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.biopha.2018.07.099","volume":"107","author":"P Zheng","year":"2018","unstructured":"Zheng, P. et al. Synthetic human monoclonal antibody targets hIL1 receptor accessory protein chain with therapeutic potential in triple-negative breast cancer. Biomed. Pharmacother. 107, 1064\u20131073. https:\/\/doi.org\/10.1016\/j.biopha.2018.07.099 (2018).","journal-title":"Biomed. Pharmacother"},{"key":"76851_CR66","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1146\/annurev.immunol.021908.132612","volume":"72","author":"C Rydberg Millrud","year":"2023","unstructured":"Rydberg Millrud, C. et al. Blockade of IL-1\u03b1 and IL-1\u03b2 signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol. Immunother. 72, 667\u2013678. https:\/\/doi.org\/10.1146\/annurev.immunol.021908.132612 (2023).","journal-title":"Cancer Immunol. Immunother"},{"key":"76851_CR67","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1038\/s41388-017-0119-6","volume":"37","author":"F Liu","year":"2018","unstructured":"Liu, F. et al. SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-\u03baB-CD47 axis. Oncogene. 37, 2394\u20132409. https:\/\/doi.org\/10.1038\/s41388-017-0119-6 (2018).","journal-title":"Oncogene"},{"key":"76851_CR68","doi-asserted-by":"publisher","first-page":"153303382199528","DOI":"10.1177\/1533033821995282","volume":"20","author":"Q Lv","year":"2021","unstructured":"Lv, Q., Xia, Q., Li, A. & Wang, Z. The potential role of IL1RAP on tumor microenvironment-related inflammatory factors in stomach adenocarcinoma. Technol. Cancer Res. Treat. 20, 1533033821995282. https:\/\/doi.org\/10.1177\/1533033821995282 (2021).","journal-title":"Technol. Cancer Res. Treat."},{"key":"76851_CR69","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1021\/bi0612824","volume":"46","author":"I Nakase","year":"2007","unstructured":"Nakase, I. et al. Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochem. 46, 492\u2013501. https:\/\/doi.org\/10.1021\/bi0612824 (2007).","journal-title":"Biochem"},{"key":"76851_CR70","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1074\/jbc.M110017200","volume":"277","author":"T Suzuki","year":"2002","unstructured":"Suzuki, T. et al. Possible existence of common internalization mechanisms among arginine-rich peptides. J. Biol. Chem. 277, 2437\u20132443. https:\/\/doi.org\/10.1074\/jbc.M110017200 (2002).","journal-title":"J. Biol. Chem."},{"key":"76851_CR71","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1021\/jp409936v","volume":"118","author":"K Baler","year":"2014","unstructured":"Baler, K. et al. Electrostatic unfolding and interactions of albumin driven by pH changes: a molecular dynamics study. J. Phys. Chem. B. 118, 921\u2013930. https:\/\/doi.org\/10.1021\/jp409936v (2014).","journal-title":"J. Phys. Chem. B"},{"key":"76851_CR72","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1186\/s40001-023-01539-z","volume":"28","author":"MM Salama","year":"2023","unstructured":"Salama, M. M., Aborehab, N. M., Mahdy, E., Zayed, N. M., Ezzat, S. M. & A. & Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials. Eur. J. Med. Res. 28, 566 (2023).","journal-title":"Eur. J. Med. Res."},{"key":"76851_CR73","doi-asserted-by":"publisher","first-page":"6478","DOI":"10.1021\/acsbiomaterials.0c01040","volume":"6","author":"J Shen","year":"2020","unstructured":"Shen, J. et al. Advances of nanoparticles for leukemia treatment. ACS Biomater. Sci. Eng. 6, 6478\u20136489 (2020).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"76851_CR74","doi-asserted-by":"publisher","unstructured":"Kim, Y. H. Heme oxygenase 1-targeted hybrid nanoparticle for chemo-and immuno-combination therapy in acute myelogenous leukemia. (2020). https:\/\/doi.org\/10.1002\/advs.202000487","DOI":"10.1002\/advs.202000487"},{"key":"76851_CR75","unstructured":"Ying-ping Jiang, J. Y. T. Holger Karsunky. Antibodies that bind membrane-bound il1rap. (Filing date: 2013-12-20)."},{"key":"76851_CR76","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/bit.24605","volume":"110","author":"KH Lim","year":"2013","unstructured":"Lim, K. H., Huang, H., Pralle, A. & Park, S. Stable, high-affinity streptavidin monomer for protein labeling and monovalent biotin detection. Biotechnol. Bioeng. 110, 57\u201367. https:\/\/doi.org\/10.1002\/bit.24605 (2013).","journal-title":"Biotechnol. Bioeng."},{"key":"76851_CR77","doi-asserted-by":"publisher","first-page":"15253","DOI":"10.1021\/acs.analchem.1c01871","volume":"93","author":"S Rahmati","year":"2021","unstructured":"Rahmati, S. et al. Computational engineering of protein L to achieve an optimal affinity chromatography resin for purification of antibody fragments. Anal. Chem. 93, 15253\u201315261. https:\/\/doi.org\/10.1021\/acs.analchem.1c01871 (2021).","journal-title":"Anal. Chem."},{"key":"76851_CR78","doi-asserted-by":"publisher","unstructured":"Rahmati, S. et al. Computational designing of the ligands of protein L affinity chromatography based on molecular docking and molecular dynamics simulations. J. Biomol. Struct. Dyn.. 1\u201311. https:\/\/doi.org\/10.1080\/07391102.2023.2268219 (2023).","DOI":"10.1080\/07391102.2023.2268219"},{"key":"76851_CR79","doi-asserted-by":"publisher","first-page":"W384","DOI":"10.1093\/nar\/gkt458","volume":"41","author":"L Heo","year":"2013","unstructured":"Heo, L., Park, H., Seok, C. & GalaxyRefine Protein structure refinement driven by side-chain repacking. Nucleic Acids Res. 41, W384\u2013W388. https:\/\/doi.org\/10.1093\/nar\/gkt458 (2013).","journal-title":"Nucleic Acids Res."},{"key":"76851_CR80","doi-asserted-by":"publisher","unstructured":"Wiederstein, M. & Sippl, M. J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 35 https:\/\/doi.org\/10.1093\/nar\/gkm290 (2007). W407-W410.","DOI":"10.1093\/nar\/gkm290"},{"key":"76851_CR81","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/protein\/8.2.127","volume":"8","author":"AC Wallace","year":"1995","unstructured":"Wallace, A. C., Laskowski, R. A. & Thornton, J. M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. Des. Select. 8, 127\u2013134 (1995).","journal-title":"Protein Eng. Des. Select."},{"key":"76851_CR82","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1093\/bioinformatics\/btx345","volume":"33","author":"M Hebditch","year":"2017","unstructured":"Hebditch, M., Carballo-Amador, M. A., Charonis, S., Curtis, R. & Warwicker, J. Protein\u2013Sol: a web tool for predicting protein solubility from sequence. Bioinform. 33, 3098\u20133100. https:\/\/doi.org\/10.1093\/bioinformatics\/btx345 (2017).","journal-title":"Bioinform"},{"key":"76851_CR83","doi-asserted-by":"publisher","unstructured":"Nguyen, M. N. et al. AllerCatPro 2.0: a web server for predicting protein allergenicity potential. Nucleic Acids res. 50, W36-W43. https:\/\/doi.org\/10.1093\/nar\/gkac446 (2022).","DOI":"10.1093\/nar\/gkac446"},{"key":"76851_CR84","first-page":"178","volume":"6","author":"RM Jouybari","year":"2018","unstructured":"Jouybari, R. M., Sadeghi, A., Khansarinejad, B., Abbasian, S. S. & Abtahi, H. Production of recombinant streptavidin and optimization of refolding conditions for recovery of biological activity. Rep. Biochem. Mol. Biol. 6, 178 (2018).","journal-title":"Rep. Biochem. Mol. Biol."},{"key":"76851_CR85","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.5012\/bkcs.2009.30.5.1101","volume":"30","author":"JS Won","year":"2009","unstructured":"Won, J. S., Kang, H. W., Nam, P. W. & Choe, M. H. B3 (Fab)-streptavidin tetramer has higher binding avidity than B3 (scFv)-streptavidin tetramer. Bull. Korean Chem. Soc. 30, 1101\u20131106. https:\/\/doi.org\/10.5012\/bkcs.2009.30.5.1101 (2009).","journal-title":"Bull. Korean Chem. Soc."},{"key":"76851_CR86","doi-asserted-by":"publisher","unstructured":"Sano, T., Smith, C. L. & Cantor, C. R. Expression and purification of recombinant streptavidin-containing chimeric proteins. Recomb Protein Protoc. : Detect. isol. 119\u2013128. https:\/\/doi.org\/10.1385\/0-89603-481-X:119 (1997).","DOI":"10.1385\/0-89603-481-X:119"},{"key":"76851_CR87","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.5012\/bkcs.2009.30.5.1101","volume":"30","author":"JS Won","year":"2009","unstructured":"Won, J. S., Kang, H. W., Nam, P. W. & Choe, M. H. B3 (Fab)-streptavidin tetramer has higher binding avidity than B3 (scFv)-streptavidin tetramer. Bull. Korean Chem. Soc. 30, 1101\u20131106 (2009).","journal-title":"Bull. Korean Chem. Soc."},{"key":"76851_CR88","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1046-5928(03)00133-5","volume":"31","author":"HP S\u00f8rensen","year":"2003","unstructured":"S\u00f8rensen, H. P., Sperling-Petersen, H. U. & Mortensen, K. K. Dialysis strategies for protein refolding: preparative streptavidin production. Protein Expr. Purif. 31, 149\u2013154. https:\/\/doi.org\/10.1016\/S1046-5928(03)00133-5 (2003).","journal-title":"Protein Expr. Purif."},{"key":"76851_CR89","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/fft2.44","volume":"1","author":"S Kamiloglu","year":"2020","unstructured":"Kamiloglu, S., Sari, G., Ozdal, T. & Capanoglu, E. Guidelines for cell viability assays. Food Front. 1, 332\u2013349. https:\/\/doi.org\/10.1002\/fft2.44 (2020).","journal-title":"Food Front."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76851-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76851-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76851-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T14:07:34Z","timestamp":1729692454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76851-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["76851"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-76851-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"16 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All benefits, profits, and intellectual rights associated with the possible patenting of this research belong exclusively to the first author, the corresponding author, and Pasteur Institute of Iran. There is no conflict of interest by the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25080"}}